Summit Therapeutics Inc.(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020 Cambridge, MA, September 29, 2020 – Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the second quarter...
Category: News
Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA
Summit Therapeutics Inc. (“Summit” or the “Company”) Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA Cambridge, MA, September 18, 2020 – Summit (NASDAQ: SMMT) today announces the completion of the company’s redomiciliation to Delaware, USA. Previously, Summit Therapeutics plc announced that the High Court of Justice in England and...
Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA
Summit Therapeutics Inc. (“Summit” or the “Company”) Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA Cambridge, MA, September 18, 2020 – Summit (NASDAQ: SMMT) today announces the completion of the company’s redomiciliation to Delaware, USA. Previously, Summit Therapeutics plc announced that the High Court of Justice in England and...
Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA
Summit Therapeutics Inc. (“Summit” or the “Company”) Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA Cambridge, MA, September 18, 2020 – Summit (NASDAQ: SMMT) today announces the completion of the company’s redomiciliation to Delaware, USA. Previously, Summit Therapeutics plc announced that the High Court of Justice in England and...
Summit Therapeutics Announces U.K. Court Approval of Scheme
Summit Therapeutics plc (“Summit” or the “Company”) Summit Therapeutics Announces U.K. Court Approval of Scheme; Expects to Complete Redomiciliation to Delaware, USA as of September 18, 2020. Oxford, UK, and Cambridge, MA, US, September 17, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) led by billionaire investor Robert W. Duggan as Executive Chairman, Chief Executive Officer...
Summit Therapeutics Announces U.K. Court Approval of Scheme
Summit Therapeutics plc (“Summit” or the “Company”) Summit Therapeutics Announces U.K. Court Approval of Scheme; Expects to Complete Redomiciliation to Delaware, USA as of September 18, 2020. Oxford, UK, and Cambridge, MA, US, September 17, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) led by billionaire investor Robert W. Duggan as Executive Chairman, Chief Executive Officer...
Summit Therapeutics Announces U.K. Court Approval of Scheme
Summit Therapeutics plc (“Summit” or the “Company”) Summit Therapeutics Announces U.K. Court Approval of Scheme; Expects to Complete Redomiciliation to Delaware, USA as of September 18, 2020. Oxford, UK, and Cambridge, MA, US, September 17, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) led by billionaire investor Robert W. Duggan as Executive Chairman, Chief Executive Officer...
Amplyx to Participate in Upcoming Antifungal Webinar Presented by Maxim Group LLC
SAN DIEGO – September 14, 2020 – Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that Ciara Kennedy, Ph.D, president and chief executive officer, has been invited to present at A Too Quiet Pandemic – Fungal Disease webinar, presented by Maxim Group LLC...
Cidara Therapeutics to Present New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two oral abstracts and seven posters at IDWeek 2020, the joint annual meeting of the Infectious...
Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional approval prior to FDA approval DUBLIN, Ireland, Sept. 10, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...